共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A modified HLA-A^(*)0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses显示文摘We previously identified human phosphatidylethanolamine-binding protein 4(hPEBP4)as an antiapoptotic protein with increased expression levels in breast,ovarian and prostate cancer cells,but low expression levels in normal tissues,which makes hPEBP4 an attractive target for immunotherapy.Here,we developed hPEBP4-derived immunogenic peptides for inducing antigen-specific cytotoxic T lymphocytes(CTLs)targeting breast cancer.A panel of hPEBP4-derived peptides predicted by peptide-MHC-binding algorithms was evaluated to characterize their HLAA2.1 affinity and immunogenicity.We identified a novel immunogenic peptide,P40–48(TLFCQGLEV),that was capable of eliciting specific CTL responses in HLA-A2.1/K^(b) transgenic mice,as well as in peripheral blood lymphocytes from breast cancer patients.Furthermore,amino-acid substitutions in the P40–48 sequence improved its immunogenicity against hPEBP4,a self-antigen,thus circumventing tolerance.We designed peptide analogs by preferred auxiliary HLA-A^(*)0201 anchor residue replacement,which induced CTLs that were crossreactive to the native peptide.Several analogs were able to stably bind to HLA-A^(*)0201 and elicit specific CTL responses better than the native sequence.Importantly,adoptive transfer of CTLs induced by vaccination with two analogs more effectively inhibited tumor growth than the native peptide.These data indicate that peptide analogs with high immunogenicity represent promising candidates for peptide-mediated therapeutic cancer vaccines. | Weihong Sun Junyi Shi Jian Wu Junchu Zhang Huabiao Chen Yuanyuan Li Shuxun Liu Yanfeng Wu Zhigang Tian Xuetao Cao Nan Li | 2018 | Cellular & Molecular Immunology2018，15，8： | 4 |
| 2 | 中国新型兽用疫苗生产的现状与存在问题分析显示文摘疫苗是用于治疗及预防某些慢性疾病和传染病等的一类生物制品,减毒活疫苗和灭活疫苗在实际生产中应用广泛,但存在如保护期短、非特异性反应强和免疫效果不理想等缺点;同时,为保证疫苗质量而在疫苗生产中加入抗生素常导致抗生素残留;因此,研发新型疫苗以解决上述问题迫在眉睫;同时,也要致力于改良现有疫苗,提高疫苗抗原转运效率和生物利用度,提高动物机体免疫力、延长抗原的体内停留时间、减少免疫剂量和次数,进而减少污染,保障动物食品安全。文章对中国新型兽用疫苗生产现状和兽用疫苗应用对抗生素的影响进行了综述,分析了兽用疫苗行业存在的问题及发展前景,并建议企业采取有效措施改变行业现状并研发新型高效疫苗。 | 赵凯 刘洪斌 毛春玲 张凤强 康宏 金政 | 2020 | 黑龙江畜牧兽医2020，，11： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员